Percutaneous ablation plus transarterial chemoembolization versus TACE in hepatocellular carcinoma received regorafenib treatment: a retrospective cohort study
Background Regorafenib serves as the second-line systemic therapy for unresectable hepatocellular carcinoma (uHCC), the clinical value of combining locoregional treatments to boost its antitumor efficacy remains under active investigation. Objectives This study aimed to explore whether adding percutaneous ablation to TACE plus regorafenib (A+T+R) yields superior clinical outcomes compared with TACE combined with regorafenib (T+R) in uHCC. Methods This study retrospectively screened consecutive patients with uHCC who received regorafenib between July 2020 and September 2024, with the final follow-up cutoff date set as December 31, 2024. Enrolled patients received either the A+T+R or T+R treatment regimen. Propensity score matching (PSM) was performed to reduce baseline selection bias. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective tumor response, disease control and treatment safety. Results A total of 162 eligible patients were enrolled (77 in the A+T+R group and 85 in the T+R group). After PSM, 46 patients remained in each group. Median PFS was comparable between the two cohorts before and after PSM (pre-PSM: 8.4 vs. 6.6 months, P = 0.084; post-PSM: 8.1 vs. 6.9 months, P = 0.301). By contrast, this significant OS benefit persisted after PSM adjustment as well (pre-PSM: 41.6 vs. 13.9 months, P < 0.001; post-PSM: 41.6 vs. 17.7 months, P = 0.022). The most common any-grade TRAE in both groups was elevated AST (62.3% vs. 45.9%). Before PSM, AST elevation was more frequent in the A+T+R group than in the T+R group ( P = 0.041); however, this difference was no longer significant after PSM ( P = 0.193). Conclusion Compared with TACE plus regorafenib, triple therapy consisting of percutaneous ablation, TACE and regorafenib was associated with longer OS with an acceptable safety profile in patients with uHCC after first-line treatment failure. However, the observed OS difference cannot be definitively attributed to percutaneous ablation given potential residual confounding. These findings should be interpreted cautiously and require further validation in prospective studies.
Authors
- songtao liu
- Jingjing Chen
- Mei Liu
- Yang Wang
- Jinhuan Wang
Institutions
- Capital Medical University (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fonc.2026.1946827
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00